AU2018376231A1 - ILDR2 antagonists and combinations thereof - Google Patents

ILDR2 antagonists and combinations thereof Download PDF

Info

Publication number
AU2018376231A1
AU2018376231A1 AU2018376231A AU2018376231A AU2018376231A1 AU 2018376231 A1 AU2018376231 A1 AU 2018376231A1 AU 2018376231 A AU2018376231 A AU 2018376231A AU 2018376231 A AU2018376231 A AU 2018376231A AU 2018376231 A1 AU2018376231 A1 AU 2018376231A1
Authority
AU
Australia
Prior art keywords
ildr2
antibody
seq
fragment
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018376231A
Other languages
English (en)
Inventor
Uwe Gritzan
John Hunter
Julia HÜTTER
Ofer Levy
Spencer LIANG
Andrew POW
Lars RÖSE
Ilan Vaknin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Compugen Ltd
Original Assignee
Bayer AG
Bayer Pharma AG
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG, Compugen Ltd filed Critical Bayer AG
Publication of AU2018376231A1 publication Critical patent/AU2018376231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018376231A 2017-11-30 2018-11-28 ILDR2 antagonists and combinations thereof Abandoned AU2018376231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30
US62/592,913 2017-11-30
PCT/EP2018/082779 WO2019105972A1 (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Publications (1)

Publication Number Publication Date
AU2018376231A1 true AU2018376231A1 (en) 2020-05-07

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018376231A Abandoned AU2018376231A1 (en) 2017-11-30 2018-11-28 ILDR2 antagonists and combinations thereof

Country Status (16)

Country Link
US (1) US11655297B2 (enExample)
EP (1) EP3717007B1 (enExample)
JP (1) JP7350740B2 (enExample)
KR (1) KR20200096223A (enExample)
CN (1) CN111655287B (enExample)
AR (1) AR113850A1 (enExample)
AU (1) AU2018376231A1 (enExample)
BR (1) BR112020010767A2 (enExample)
CA (1) CA3083675A1 (enExample)
IL (1) IL274751B2 (enExample)
MX (1) MX2020005483A (enExample)
PE (1) PE20200956A1 (enExample)
RU (1) RU2020121533A (enExample)
SG (1) SG11202003323TA (enExample)
TW (1) TW201934119A (enExample)
WO (1) WO2019105972A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952910A1 (en) * 2019-04-11 2022-02-16 Bayer Aktiengesellschaft Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP2769729B1 (en) 2007-09-04 2019-01-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20130209463A1 (en) * 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
AU2012277376B2 (en) * 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2015512616A (ja) * 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
US20170233473A1 (en) * 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
PT3789042T (pt) 2014-04-10 2025-01-14 Daiichi Sankyo Europe Gmbh Método para produzir conjugado anticorpo-fármaco anti-her3
AU2016323582B2 (en) 2015-09-16 2022-09-15 Ablexis, Llc Anti-CD115 antibodies

Also Published As

Publication number Publication date
MX2020005483A (es) 2020-08-27
EP3717007A1 (en) 2020-10-07
KR20200096223A (ko) 2020-08-11
CN111655287A (zh) 2020-09-11
AR113850A1 (es) 2020-06-17
CN111655287B (zh) 2024-12-27
IL274751B1 (en) 2024-07-01
TW201934119A (zh) 2019-09-01
WO2019105972A1 (en) 2019-06-06
EP3717007B1 (en) 2025-09-17
IL274751A (en) 2020-07-30
US20200369769A1 (en) 2020-11-26
EP3717007C0 (en) 2025-09-17
JP7350740B2 (ja) 2023-09-26
IL274751B2 (en) 2024-11-01
BR112020010767A2 (pt) 2020-11-24
SG11202003323TA (en) 2020-05-28
US11655297B2 (en) 2023-05-23
JP2021504404A (ja) 2021-02-15
CA3083675A1 (en) 2019-06-06
PE20200956A1 (es) 2020-09-24
RU2020121533A (ru) 2021-12-30

Similar Documents

Publication Publication Date Title
US11447551B2 (en) Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
US11655297B2 (en) ILDR2 antagonists and combinations thereof
JP2021525080A (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
AU2018336520B2 (en) Novel anti-CD19 antibodies
JP2021524251A (ja) Ｃｄ３に特異的な抗体及びその使用
AU2018242157B2 (en) Compositions and methods for treating lung cancer
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
JP7625516B2 (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CN116940595A (zh) 抗tigit抗体及其用途
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
JP2020075879A (ja) 抗ｒｎｆ４３抗原結合分子及びその使用
HK40028721A (en) Ildr2 antagonists and combinations thereof
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
RU2791445C2 (ru) Новые анти-cd19-антитела
US20220169736A1 (en) Combinations of anti-ildr2 antibodies and pd-1 antagonists
HK40028721B (zh) Ildr2拮抗剂及其组合
JP2024528217A (ja) 二重特異性抗体および使用方法
TW202523352A (zh) 抗ｐｖｒｉｇ或ｔｉｇｉｔ的抗體、由其構建的雙特異性抗體、其製備方法和用途
JP2024534186A (ja) 副作用が低減された抗ｃｅｃａｍ６抗体
HK40057228A (en) Combinations of anti-ildr2 antibodies and pd-1 antagonists

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted